吉非替尼治疗肺鳞癌的效果及对患者CRP水平的影响
|
摘要
目的探究吉非替尼治疗肺鳞癌的效果及对患者CRP水平的影响。方法将我院2017年2月至2018年12月收治的78例肺鳞癌患者按照随机数字表法分为观察组(吉非替尼治疗)与对照组(常规治疗),每组39例。比较两组的治疗效果。结果治疗后,两组CRP水平均降低,且观察组低于对照组(P<0.05)。观察组的治疗总有效率高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论吉非替尼治疗肺鳞癌能够促进患者CRP水平改善,且不增加不良反应,效果显著,值得推广应用。
Objective To investigate the effect of gefitinib in the treatment of lung squamous cell carcinoma and its effect on C-reactive protein(CRP) level. Methods From February 2017 to December 2018, 78 patients with lung squamous cell carcinoma were randomly divided into observation group(gefitinib treatment) and control group(routine treatment), with39 cases in each group. The therapeutic effects of the two groups were compared. Results After treatment, CRP levels in both groups decreased, and that in the observation group was lower than the control group(P<0.05). The total effective rate of treatment in the observation group was higher than that of the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Gefitinib in the treatment of lung squamous cell carcinoma can promote the improvement of CRP level without increasing adverse reactions. It has a remarkable effect, which is worthy of popularization and application.
Objective To investigate the effect of gefitinib in the treatment of lung squamous cell carcinoma and its effect on C-reactive protein(CRP) level. Methods From February 2017 to December 2018, 78 patients with lung squamous cell carcinoma were randomly divided into observation group(gefitinib treatment) and control group(routine treatment), with39 cases in each group. The therapeutic effects of the two groups were compared. Results After treatment, CRP levels in both groups decreased, and that in the observation group was lower than the control group(P<0.05). The total effective rate of treatment in the observation group was higher than that of the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Gefitinib in the treatment of lung squamous cell carcinoma can promote the improvement of CRP level without increasing adverse reactions. It has a remarkable effect, which is worthy of popularization and application.
引文
[1]孙晓军,李杰.非小细胞肺癌患者血浆表皮生长因子受体基因突变检测及其临床意义[J].中华临床医师杂志:电子版,2016,13(7):104-105.
[2]金建江,胡启擂,邱滔.康莱特注射液联合吉非替尼对晚期肺癌患者炎性因子与免疫功能的影响[J].中国生化药物杂志,2016,15(12):147-150.
[3]陈凯,李亚洁,张春峰,等.国产吉西他滨联合顺铂治疗晚期肺鳞癌及肺腺癌疗效分析[J].中国肿瘤临床与康复,2016,21(4):366-369.
[4]王俊华,何靖康,秦正红,等.南美响尾蛇神经毒素对吉非替尼诱导人肺鳞癌SK-MES-1细胞凋亡的影响[J].苏州大学学报:医学版,2017,31(1):218-219.
[5]何海洋,齐陆玉,侯伊玲.阻断EGFR影响肺鳞癌肿瘤微环境Treg细胞及IL-1A表达[J].中国肺癌杂志,2017,14(3):182-184.
[6]吴洪波,李明智,史亮,等.EGFR-TKIs在晚期EGFR受体突变肺鳞癌患者中的临床应用[J].中国肿瘤临床,2016,22(24):137-138.
[7]邓立春,张瑶,沈伟生.吉非替尼治疗厄洛替尼致间质性肺炎后进展的晚期肺鳞癌1例[J].临床肿瘤学杂志,2017,16(1):86-87.
[8]杨光,张丹,张曙光.吉非替尼对晚期肺鳞癌患者四种外周血血清肿瘤标志物浓度及近期疗效的影响[J].临床误诊误治,2015,13(3):90-93.
[2]金建江,胡启擂,邱滔.康莱特注射液联合吉非替尼对晚期肺癌患者炎性因子与免疫功能的影响[J].中国生化药物杂志,2016,15(12):147-150.
[3]陈凯,李亚洁,张春峰,等.国产吉西他滨联合顺铂治疗晚期肺鳞癌及肺腺癌疗效分析[J].中国肿瘤临床与康复,2016,21(4):366-369.
[4]王俊华,何靖康,秦正红,等.南美响尾蛇神经毒素对吉非替尼诱导人肺鳞癌SK-MES-1细胞凋亡的影响[J].苏州大学学报:医学版,2017,31(1):218-219.
[5]何海洋,齐陆玉,侯伊玲.阻断EGFR影响肺鳞癌肿瘤微环境Treg细胞及IL-1A表达[J].中国肺癌杂志,2017,14(3):182-184.
[6]吴洪波,李明智,史亮,等.EGFR-TKIs在晚期EGFR受体突变肺鳞癌患者中的临床应用[J].中国肿瘤临床,2016,22(24):137-138.
[7]邓立春,张瑶,沈伟生.吉非替尼治疗厄洛替尼致间质性肺炎后进展的晚期肺鳞癌1例[J].临床肿瘤学杂志,2017,16(1):86-87.
[8]杨光,张丹,张曙光.吉非替尼对晚期肺鳞癌患者四种外周血血清肿瘤标志物浓度及近期疗效的影响[J].临床误诊误治,2015,13(3):90-93.